Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 2/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15463082 | 0.90 | NOD1 (0.56) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15463083 | 0.86 | FOLH1 (0.46) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL17011763 | 0.85 | HDAC3 (0.41) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL14535265 | 0.85 | HDAC3 (0.41) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2167433 | 0.84 | FOLH1 (0.55) | FOLH1NOD1 | |
| SCHEMBL5239846 | 0.83 | NOD1 (0.56) | HDAC2NOD1 | |
| SCHEMBL16800415 | 0.80 | HDAC3 (0.44) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13301145 | 0.80 | FOLH1 (0.56) | FOLH1NOD1FNTAFNTB | |
| SCHEMBL9729998 | 0.80 | HDAC3 (0.37) | FOLH1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL19261030 | 0.79 | FOLH1 (0.56) | FOLH1ALBNOD1SMN1; SMN2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095467-B1 | ANTIBODY-ENZYME CONJUGATE | VENTANA MED SYST INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2963011-B1 | MOLECULAR CONJUGATE | VENTANA MED SYST INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-3095467-A1 | MOLECULAR CONJUGATE | Ventana Medical Systems, Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160195540-A1 | Molecular Conjugate | VENTANA MED SYST INC (US) | 2016-07-07 | — | — | US | disclosed |
| US-9310373-B2 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2963011-A1 | MOLECULAR CONJUGATE | Ventana Medical Systems, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20140205995-A1 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20100136652-A1 | Molecular Conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100136652-A1 | Molecular Conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2010-06-03 | — | — | US | disclosed |
| WO-2007062177-A2 | MOLECULAR CONJUGATE | VENTANA MEDICAL SYSTEMS, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070117153-A1 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2007-05-24 | — | — | US | disclosed |
| US-20070117153-A1 | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160195540-A1 | Molecular Conjugate | CA12, FCGR2A, CA14 | FOLH1 10/4885HDAC3 1737/4885HDAC4 2485/4885 |
| US-20100136652-A1 | Molecular Conjugate | CA12, FCGR2A, CA14 | FOLH1 10/4885HDAC3 1737/4885HDAC4 2485/4885 |
| US-20070117153-A1 | Molecular conjugate | CA12, FCGR2A, CA14 | FOLH1 10/4885HDAC3 1737/4885HDAC4 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.